Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Pennsylvania House Approves Bill Allowing Young Adults To Remain On Parents' Health Insurance Policies Up To Age 29
The Pennsylvania House last week voted to approve a bill that allows state residents up to age 29 to be added to or remain on their parents" health insurance plans as long as they live in the state or are full-time students, the Harrisburg Patriot-News reports. They also must be single and not have dependents.According to national data, young adults between ages 19 and 29 make up the largest segment of the U.S. population without health insurance. The Pennsylvania Insurance Department estimates that nearly 400,000 state residents in that age group are uninsured. The bill allows employers to decide if they want to offer the coverage option to their employees. Families choosing to add adult dependents to their health plans will have higher premiums. Gov. Ed Rendell (D) is expected to sign the bill, which the state Senate approved in March (Thompson, Harrisburg Patriot-News, 5/14). Prescription for Pennsylvania Plan
generic viagra online
NEJM Explores The Value-Based System Approach To Health Reform
In a New England Journal of Medicine perspective published online last night, Harvard Business School Professor Michael E. Porter outlines a national health care strategy. Recognizing "a new openness to changing a system that we all agree is broken," Porter emphasizes the need for a "value-based system" that both moves toward universal insurance coverage and restructures the care delivery system. Porter offers six steps critical to achieving such a system:
News of the day
No Evidence That Combined DTP-HBV-Hib Vaccine Works Better
There is no evidence that giving infants a combination vaccine for diphtheria (D), tetanus (T), pertussis (P), hepatitis B (HBV), and Haemophilus influenza type B (Hib) protects them as effectively as separate vaccines, according to the results of a new Cochrane review.
Oncology

Cegedim Dendrite Launches Innovative COUNTERxFEIT DETECT Program

Cegedim Dendrite announced the launch of COUNTERxFEIT DETECT, a new offering that will assist pharmaceutical companies in identifying counterfeit product and determining where it entered their United States supply chains. Cegedim Dendrite is the leading provider of compliance technology solutions and services in the pharmaceutical industry. Counterfeit medicines represent a significant public health and safety issue for consumers. It also poses serious business and financial risks for manufacturers, including possible liability issues, lost revenue, erosion of brand confidence and negative public perception. COUNTERxFEIT DETECT is designed for pharmaceutical companies that need to identify and determine the of counterfeit, contaminated or adulterated product. Cegedim Dendrite facilitates this by coordinating the purchase of non-controlled, finished drug products from contract manufacturers or distributors, using an independent pharmaceutical buyer. The product is shipped to a testing facility or the pharmaceutical company"s analytical lab, where the product is analyzed. "Drug counterfeiting is a concern in the pharmaceutical industry with estimates indicating that upward of 8% of pharmaceutical medicines worldwide may be counterfeit," explained Bill Buzzeo, Cegedim Dendrite Vice President and General Manager, Compliance Solutions and OneKey. "As part of their anti-counterfeiting programs, pharmaceutical companies should acquire finished drug products within the supply chain for analysis and testing to ensure their quality. We seamlessly facilitate that process, and as far as we know, we"re the only company that offers this type of program." Cegedim Dendrite"s independent purchasing of finished drug product takes the burden off the pharmaceutical company"s internal res. COUNTERxFEIT DETECT is fully secure and includes appropriate audit trail documentation that provides insight into the full acquisition chain associated with the independent pharmacy"s purchase. "If an independent party is making the purchase," said Buzzeo, "the pharmaceutical company can better show that they had a random sample for testing and that the process was not tainted by anyone internally with false motive." Cegedim Dendrite has been providing comprehensive compliance solutions to a broad range of pharmacy clients for 20 years. The company employs former state and federal regulators whose firsthand experience with compliance, fraud and abuse issues enable them to develop real-world prevention programs. About Cegedim Dendrite Cegedim Dendrite is the life sciences industry"s leading provider of Customer Relationship Management (CRM) solutions. Pharmaceutical by design, the company"s innovative business solutions and global reach incorporate a thorough understanding of local, regional and worldwide trends. Cegedim Dendrite enables more than 200,000 users in many of the world"s top companies to stay ahead of market challenges. Cegedim Dendrite also provides sales, marketing and regulatory compliance solutions in more than 80 countries. Cegedim Dendrite is part of the France-based Cegedim S.A. Group. To learn more, please visit http://www.cegedimdendrite.com. Cegedim


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009